CalciMedica director Guerard gets 20,000-share option
The option's monthly vesting began August 19, 2026, and it will be fully vested on the date of CalciMedica's 2027 annual meeting.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
CalciMedica, Inc. director Frederic Guerard acquired a director stock option on October 1, 2026, covering 20,000 shares of common stock. The option has an exercise price of $1.64 per share and expires September 30, 2036. After the award, his reported direct option position covered 20,000 shares.
Beginning August 19, 2026, one-twelfth of the shares subject to the option vest in equal monthly installments over one year. The option will be fully vested on the date of CalciMedica's 2027 annual meeting.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Director Stock Option (Right to Buy) F1 | 20,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. Beginning August 19, 2026, 1/12th of the shares subject to the option vest in equal monthly installments over a one year period, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.
Key Figures
Key Terms
Director Stock Option (Right to Buy) financial
vest financial
fully vested financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many options did CalciMedica director Frederic Guerard receive?
AI-generated analysis. How Rhea-AI works. Not financial advice.